

Monitoring of Dutch waters by CALUX panel



Sander van der Linden

Biodetection Systems



Why monitor surface waters with bioassays?

- **Compounds are present – as a complex mixture – that can influence biological pathways**
- **Some compounds can do this at relatively low concentrations**
- **We cannot determine all compounds chemically**
- **.... and if we could we would most of the time not know their biological effect(s)**



Bioassay monitoring - past

- **Bioanalysis of endocrine disruptors**
 - Equals estrogens in many cases
 - Screening projects (e.g. LOES)
- **Chemical analysis**
 - TIE in combination with assays
 - Natural hormones, synthetic hormones, industrial chemicals, pesticides







What classes of compounds can be expected?

- **Pharmaceuticals**
 - potent compounds, biological activity intended for humans/animals, low concentration?
- **Pesticides**
 - Biological activity intended for plants/insect/mammals, non-human targets, possibly potent compounds
- **Personal Care Products**
 - Activity non-intended, low potency
- **Excretion products**
 - (Degradation products of) natural ligands, possibly potent
- **Industrial chemicals**
 - High volume, low potency?, biological activity generally not intended


Bioassay monitoring - present

- CALUX panel for four different types of hormonal activity (AR, PR, GR, ER)



RIWA (2009)

- **Screen for activity on multiple pathways**
 - Adverse outcome pathways (Ankley et al (2010), NRC, Tox21)




- **But how many pathways?**
 - Focus on endocrine disruption, reproductive toxicity, genotoxicity




Which pathways should be monitored?

Non-genotoxic mechanisms

Genotoxic mechanisms



Which assays are available?



endogenous
situation

selective

selective and
responsive

- **Nuclear receptors**

- DR, PAH, ER(α , β), AR, PR, GR, TR β , RAR, PPAR(α , γ), LXR

- **Signaling pathways**










- NF κ B, Nrf2, TCF, ESRE, AP-1, p21, p53, Hif1 α



Expand panel with additional pathways

- **P53**
 - marker for genotoxic stress
 - with and without metabolic activation
- **Nrf2**
 - involved in oxidative stress response
- **PPARgamma**
 - involved in cellular differentiation and metabolism
 - part of PPARgamma receptor family (under development)
- **And additional assays....**

Which types of activity are detected?




Hormone receptors

DNA damage



How to incorporate bioassays in monitoring?



Trigger values for bioassays

- To use bioassay results for screening, trigger values are needed!

Trigger values

- > more detailed examination warranted
 - < health risks can be waived
- Bioassay results indicative for total amount of active compounds...
 - ...but compound identity is unknown!






Point of departure for trigger values

- **Provisional Acceptable or Tolerable Daily Intake (ADI/TDI) of reference compound (WHO/JECFA)**
- **Pharmacokinetic factors for bioavailability reference compound**
- **“Worst-case” assumptions pharmacokinetic factors other compounds**
- **WHO body weight (60 kg), volume drinking water (2L)**
- **WHO allocation factor for drinking water (20%)**

How to derive trigger values?





Trigger value for estrogens (as example)

ADI estradiol (E2)	50 ng/kg bw/d (<i>WHO/JECFA</i>)
Oral bioavailability	5%
Free fraction	2%
Available concentration	$50 \times 0.05 \times 0.02 = 0.05$ ng/kg/bw
External equivalent dose	$0.05 / 0.50 / 0.50 = 0.2$ ng E2-eq/kg bw/d
Trigger value	0.2×60 kg bw / 2 L x 20% = 1.2 ng E2-eq/L



With the help of....



BioDetection Systems

Bart van der Burg
Harrie Besselink
Barbara Lusenburg
Snezana Zeljkovic
Bram Brouwer

KWR

Watercycle Research Institute

Merijn Schriks
Water Brand
Minne Heringa

Thank you for your attention!